Litfulo (ritlecitinib) is a novel kinase inhibitor that received FDA approval in 2023 for the treatment of severe Alopecia Areata. Vitiligo, a disease that is the #1 cause of skin depigmentation worldwide, is the next indication in the brand’s pipeline and is expected to be filed in major markets later this year. The **US Vitiligo […]
